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ABSTRACT
Objective Gastric cancer is a major gastrointestinal
malignancy for which targeted therapies are emerging as
treatment options. This study sought to identify the most
prevalent molecular targets in gastric cancer and to
elucidate systematic patterns of exclusivity and co-
occurrence among these targets, through comprehensive
genomic analysis of a large panel of gastric cancers.
Design Using high-resolution single nucleotide
polymorphism arrays, copy number alterations were
proﬁled in a panel of 233 gastric cancers (193 primary
tumours, 40 cell lines) and 98 primary matched gastric
non-malignant samples. For selected alterations, their
impact on gene expression and clinical outcome were
evaluated.
Results 22 recurrent focal alterations (13 ampliﬁcations
and nine deletions) were identiﬁed. These included both
known targets (FGFR2, ERBB2) and also novel genes in
gastric cancer (KLF5, GATA6). Receptor tyrosine kinase
(RTK)/RAS alterations were found to be frequent in
gastric cancer. This study also demonstrates, for the ﬁrst
time, that these alterations occur in a mutually exclusive
fashion, with KRAS gene ampliﬁcations highlighting
a clinically relevant but previously underappreciated
gastric cancer subgroup. FGFR2-ampliﬁed gastric
cancers were also shown to be sensitive to dovitinib, an
orally bioavailable FGFR/VEGFR targeting agent,
potentially representing a subtype-speciﬁc therapy for
FGFR2-ampliﬁed gastric cancers.
Conclusion The study demonstrates the existence of
ﬁve distinct gastric cancer patient subgroups, deﬁned by
the signature genomic alterations FGFR2 (9% of
tumours), KRAS (9%), EGFR (8%), ERBB2 (7%) and MET
(4%). Collectively, these subgroups suggest that at least
37% of gastric cancer patients may be potentially
treatable by RTK/RAS directed therapies.
Gastric adenocarcinoma, or gastric cancer is
a leading cause of global cancer mortality with an
overall 5-year survival rate of approximately 20%.
1 2
Particularly prevalent in many Asian countries,
3
most gastric cancer patients present at advanced
disease stages and are treated by palliative chemo-
therapy, with median survival times of 11e12
months.
4 In addition to standard cytotoxic regi-
mens, targeted therapies, which are small molecules
or antibodies designed to disrupt the activity of
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Signiﬁcance of this study
What is already known about this subject?
< Gastric cancer patients with ERBB2-ampliﬁed
tumours can clinically beneﬁt from ERBB2-
targeted therapies. Similar to ERBB2, several
other molecularly targeted therapies are
currently being evaluated in gastric cancer.
< Little is known regarding which molecular
targets are concurrently expressed in the same
gastric tumours, or independently in different
tumours.
< Unlike other cancer types, activating mutations
in KRAS are also rarely observed in gastric
cancer.
What are the new ﬁndings?
< This study identiﬁed 22 recurrent genomic
alterations in gastric cancer, comprising both
known gastric cancer targets (FGFR2, ERBB2)
and genes not previously reported to be
ampliﬁed in gastric cancer (KLF5, GATA6).
< Genes related to RTK/RAS signalling, in partic-
ular FGFR2, KRAS, ERBB2, EGFR and MET are
frequently ampliﬁed in gastric cancer in a mutu-
ally exclusive manner.
< FGFR2-ampliﬁed gastric cancers exhibited sensi-
tivity to dovitinib, an orally bioavailable targeted
therapy.
< KRAS ampliﬁcations, frequently observed in
gastric cancer, are signiﬁcantly associated
with adverse prognosis.
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Stomachspeciﬁc oncogenic signalling pathways, have recently emerged as
a promising therapeutic strategy. In the recent ToGA trial,
4
trastuzumab, an anti-HER2/ERBB2 targeting antibody, improved
the overall survival of patients with HER2-positive tumours
when combined with chemotherapy. However, because only
7e17% of gastric cancer patients are HER2 positive (either gene
ampliﬁcation or overexpression) and thus suitable candidates for
anti-HER2 therapy,
5e7 further research is warranted to increase
the population of gastric cancer patients for which targeted
treatments are clinical options.
Reﬂecting this urgency, several other targeted therapies are
currently undergoing preclinical and clinical testing in gastric
cancer, directed against diverse oncogenic proteins including
signalling receptors, histone deacetylases and cellular
proteins.
8e10 However, because most of these targeted therapies
were originally designed against proteins expressed or discovered
in other cancers (eg, trastuzumab for breast cancer), in many
cases surprisingly little is actually known either regarding the
true prevalence of their oncogenic targets in primary gastric
cancers, or if expression of these oncogenic targets is correlated
with key clinico-pathological parameters such as patient
outcome. As one example, the FGFR2 receptor tyrosine kinase
(RTK) has previously been proposed as a potential therapeutic
target in gastric cancer.
11 However, most FGFR2-related studies
in gastric cancer have been primarily restricted to in-vitro
cultured cell lines,
12 13 and little data is available regarding the
true prevalence of FGFR2 gene ampliﬁcation in primary gastric
cancers particularly at the high-resolution genomic level. As
such, a comprehensive and unbiased survey to identify the most
prevalent molecular targets in gastric cancer could facilitate
many aspects of gastric cancer translational research, for
example, in focusing clinical trials efforts on those therapies that
might beneﬁt the greatest numbers of gastric cancer patients.
Besides identifying the most prevalent targets, recent ﬁndings
have also highlighted the importance of determining if certain
combinations of targets are expressed either independently from
one another (ie, mutual exclusivity) or co-occurring in the same
tumour. Knowledge of such ‘inter-target relationships’ (ITR) can
shed critical insights into the signalling networks of a cancer cell,
case examples being the mutual exclusivity of KRAS and BRAF
activating mutations in colorectal cancer, and the exclusivity of
EGFR and KRAS mutations in lung cancer.
14 15 Identifying ITR
may also highlight promising drug combinations for combina-
tion therapy, and suggest rational molecular criteria for patient
inclusion and exclusion in clinical trials. Recent studies exem-
plifying both the basic and clinical importance of ITR include
ERBB2 and PIK3CA, in which co-occurring PIK3CA mutations in
ERBB2-positive breast cancers can modulate clinical responses to
trastuzumab,
16 and EGFR and MET, in which clinical resistance
to geﬁtinib in EGFR-mutated lung cancers can be caused by
co-existing MET gene ampliﬁcations.
17
In this study, we sought to identify the most prevalent
molecular targets in gastric cancer and to elucidate their ITR. To
achieve this aim, we performed, to our knowledge, the largest
and most comprehensive survey of genomic copy number
alterations in gastric cancer to date, proﬁling more than 230
gastric cancers (>190 primary tumours and 40 cell lines) on high
resolution single nucleotide polymorphism (SNP) arrays
containing over 1 million array probes.
MATERIALS AND METHODS
Patient samples were obtained from institutional tissue reposi-
tories of the participating centres. Primary gastric tumours were
collected with approvals from the respective institutional
research ethics review committees and with signed patient
informed consent. ‘Normal’ (ie, non-malignant) samples used in
this study refer to samples harvested from the stomach, from
sites distant from the tumour and exhibiting no visible evidence
of tumour or intestinal metaplasia/dysplasia upon surgical
assessment. Clinicopathological information of these patients
including age, disease stage, histological subtype, treatment and
anatomical location, are included in supplementary table S1
(available online only). Only three patients received neo-adjuvant
or preoperative chemotherapy before surgery. Gastric cancer cell
lines were obtained from commercial sources (American Type
Culture Collection, Japan Health Science Research Resource
Bank) or from collaborators (Yonsei Cancer Centre, South Korea).
Genomic DNA were extracted from ﬂash-frozen tissues or cell
pellets using a Qiagen genomic DNA extraction kit (Qiagen,
Hilden, Germany), and proﬁled on Affymetrix SNP 6.0 arrays
(Affymetrix, Santa Clara, California, USA) according to the
manufacturer’s speciﬁcations. The array data have been depos-
ited into the National Centre for Biotechnology Information’s
Gene Expression Omnibus under accession number GSE31168.
Tumour-speciﬁc genomic alterations were identiﬁed by normal-
ising the primary gastric cancer proﬁles against the primary
matched gastric normal samples. Analyses were performed using
the genomic identiﬁcation of signiﬁcant targets in cancer
(GISTIC) algorithm
18 using false discovery rate q-value thresh-
olds of less than 0.25 for broad regions and less than 0.001 for
focal regions, similar to those used in previous reports.
19e21
Additional details, including methods associated with
dimension reduction permutation (DRP), ﬂuorescence in-situ
hybridisation (FISH) assays, and functional assays, are presented
in the supplementary materials (available online only).
RESULTS
Genomic landscape of Copy Number Alteration (CNA) in gastric
cancer
We proﬁled genomic DNA samples from 193 primary gastric
cancers, 98 primary matched gastric normal samples and 40
gastric cancer cell lines on Affymetrix SNP6 microarrays
containing approximately 1.8 million probes with a median
interprobe spacing of 680 bp. To identify tumour-speciﬁc
genomic alterations and exclude regions of potential germ line
copy number variation, we normalised the gastric cancer proﬁles
against the matched gastric normal samples (see the Methods
section and supplementary ﬁgure S1 (available online only) for
representative proﬁles). On average, we observed approximately
150 genomic aberrations per gastric cancer, comprising a mixture
of broad and focally altered regions. Frequently ampliﬁed broad
chromosomal regions included 1q, 3q, 5p, 6p, 7pq, 8q, 12pq, 13q,
Signiﬁcance of this study
How might it impact on clinical practice in the foreseeable
future?
< Dovitinib may represent a subtype-speciﬁc therapy for FGFR2-
ampliﬁed gastric cancers.
< KRAS genomic ampliﬁcation status should be assessed in
clinical trials involving therapies targeting upstream RTK.
< Genomic ampliﬁcations in RTK/RAS components deﬁne ﬁve
distinct gastric cancer molecular subgroups, to which differing
therapies can be allocated. In total, 37% of the gastric cancer
population may be treatable by RTK/RAS targeting agents.
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Stomach18pq, 19p, 20pq and 21p (frequencies 9.8e33.7%), and
frequently deleted chromosomal regions included 3p, 4pq, 5q,
6q, 8p, 9p, 9q, 11q, 12p, 14q, 16q, 17p, 18p, 18q, 19p 21q and 22q
(frequencies 7.8e13.0%) (ﬁgure 1A). These results are highly
concordant with previous comparative genomic hybridisation
(CGH/aCGH) studies of gastric cancer.
22e27
Figure 1 Broad and focal genomic
alterations in gastric cancer. (A) Large-scale
copy number alterations. The diagram shows
a CNA plot where chromosomal regions of the
22 autosomes are represented on the y-axis,
and genomic identiﬁcation of signiﬁcant
targets in cancer (GISTIC) computed false
discovery rate (FDR) q-values are on the
x-axis. Chromosomal deletions are on the left
(blue) and ampliﬁcations are on the right (red).
Signiﬁcantly altered regions of broad CNA are
highlighted at the sides, as blue and red bars
(GISTIC q value <0.25). (B) Focal alterations.
Genes localised within the peaks of the focally
altered regions are speciﬁed. Genes in square
brackets are genes that lie immediately
adjacent to the alteration peak (eg, MYC).
Signiﬁcantly altered focal events (GISTIC
q-value <0.001) are highlighted at the sides
and summarised in table 1.
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StomachFocal genomic alterations highlight 22 potential targets in
gastric cancer
We identiﬁed 22 focal genomic alterations, deﬁned as narrow
regions (typically <100 kb) exhibiting high levels of copy number
gain or loss (table 1). Among the ampliﬁed genes were several
oncogenes previously known to be ampliﬁed in gastric can-
cer, including EGFR, ERBB2/HER2 and CCND1 (ﬁgure 1B).
6 28 29
Among the focally deleted genes in gastric cancer, we re-identiﬁed
FHIT, RB1, CDKN2A/B,a n dWWOX, also previously known
to be deleted in gastric cancer.
30e34 The re-discovery of these
classic oncogenes and tumour suppressor genes supports the
accuracy of the SNP6 array data. To validate the array data
further, we performed ERBB2 immunohistochemistry on 146 of
the 193 cases (see supplementary ﬁgure S2, available online
only), and conﬁrmed a signiﬁcant association between ERBB2
copy number gain and ERBB2 protein expression (p<0.01,
Fisher’s exact test, supplementary table S2, available online
only).
Besides known genes, the analysis also revealed novel genes
not previously reported in gastric cancer. These included
genomic ampliﬁcation of the transcription factors GATA6 and
KLF5, and somatic deletions in PARK2, PDE4D, CSMD1 and
GMDS. Recent data suggest that GATA factors in particular
may play an oncogenic role in certain gastrointestinal cancers,
for example, GATA6 has been shown to be ampliﬁed in pancre-
atic cancer.
35 PARK2 and PDE4D deletions have also recently
been observed in glioblastoma and lung adenocarcinomas.
19 20
Using immunohistochemistry, we conﬁrmed that one of these
novel deleted genes, CSMD1, was downregulated or absent in
approximately 40% of primary gastric cancers at the protein
level, but was highly expressed in normal gastric epithelium
(n¼42; supplementary ﬁgure S3, available online only).
A network of non-random ITR deﬁne relationships between
gastric cancer targets
A major goal of our study was to identify non-coincidental ITR
between the 22 gastric cancer targets in a systematic, unbiased
and statistically rigorous manner. We developed a statistical
method called DRP for this purpose. Brieﬂy, DRP identiﬁes non-
random ITR between targets by comparing the numbers of
tumour samples exhibiting a particular ITR (associations
between distinct alterations) against a null distribution of
background ITR generated through random permutation. The
supplementary information (available online only) provides
a detailed description of the DRP method. Compared with other
methods such as hierarchical clustering and correlation tests,
DRP provides additional sensitivity in identifying ITR, without
requiring a priori knowledge of speciﬁc gene functions (see
supplementary ﬁgure S4, available online only).
We uncovered several signiﬁcant ITR associated with the 22
gastric cancer targets. These target pairs were either ampliﬁed in
a mutually exclusive manner in different tumours, or co-
ampliﬁed in the same tumour (ﬁgure 2 and supplementary table
S3, available online only). Functionally, the gastric cancer ITR
tended to involve two speciﬁc target classesdgenes related to
RTK/RAS signalling, including KRAS, FGFR2, ERBB2, EGFR and
MET, and genes related to transcription factor biology (MYC,
GATA4, GATA6 and KLF5). For example, tumours exhibiting
KRAS ampliﬁcations were largely distinct from tumours exhib-
iting ERBB2 or FGFR2 ampliﬁcation (p¼0.02 and p¼0.005 for
Table 1 Focal regions of CNA regions in gastric cancer
CNA Chr Start End Length (kb) Cytoband Q value Genes in peak
Ampliﬁcation
1 10 123336181 123337713 1.5 10q26.13 3.9561E-99 FGFR2
2 8 128628340 128670251 41.9 8q24.21 7.984E-27 [MYC]
3 19 34982652 35002397 19.7 19q12 3.1439E-23 CCNE1
4 12 25213920 25336398 122.5 12p12.1 1.5713E-14 KRAS, CASC1, LYRM5
5 18 17947474 18040783 93.3 18q11.2 1.0616E-13 GATA6
6 5 21377838 21406308 28.5 5p14.3 9.501E-12 [CDH12]
7 7 91921079 92111471 190.4 7q21.2 2.0612E-10 CDK6, PEX1, GATAD1,
DKFZP564O0523,
FAM133B
8 8 11346688 11659701 313.0 8p23.1 9.0544E-10 BLK, GATA4, C8orf13
9 7 55237447 55373693 136.2 7p11.2 2.4109E-09 EGFR
10 17 35102118 35136335 34.2 17q12 3.8268E-09 ERBB2
11 13 72528937 72770614 241.7 13q22.1 1.4729E-07 KLF5
12 11 69161019 69306967 145.9 11q13.2 9.1737E-07 CCND1, FGF4, FGF19,
ORAOV1
13 7 115987034 116178774 191.7 7q31.2 0.00012527 CAV1, MET
Deletion
1 3 60447451 60472964 25.5 3p14.2 3.4002E-41 FHIT
2 8 4182635 4182916 0.3 8p23.2 1.0797E-18 CSMD1
3 9 21953419 21995192 41.8 9p21.3 1.0299E-17 CDKN2A, CDKN2B
4 6 2019538 2068880 49.3 6p25.3 1.7756E-14 GMDS
5 16 77269209 77293232 24.0 16q23.1 5.4871E-12 WWOX
6 6 162551244 162610874 59.6 6q26 2.1056E-11 PARK2
7 13 47806677 47809375 2.7 13q14.2 3.3682E-11 RB1
8 5 58436441 58569237 132.8 5q11.2 1.6661E-10 PDE4D
9 9 9524063 9675303 151.2 9p23 1.2287E-09 PTPRD
Focal recurrent CNA (ampliﬁcations and deletions) identiﬁed by genomic identiﬁcation of signiﬁcant targets in cancer (GISTIC). Genes
previously reported as oncogenes or tumour suppressor genes are highlighted in bold. Start and end indicates the boundary of the
region identiﬁed. Length indicates size of each region identiﬁed. Q value represents the signiﬁcance of the recurrent CNA region across
all the gastric tumours. Genes in peak, genes covered by the corresponding region, a square bracket indicates that the gene lies
immediately adjacent to the peak.
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StomachKRAS/ERBB2 and KRAS/FGFR2, respectively), while tumours
exhibiting METampliﬁcations were distinct from tumours with
FGFR2 ampliﬁcations (p¼0.03; ﬁgure 2A and supplementary
table S3, available online only). Likewise, GATA4, GATA6 and
KLF5 were signiﬁcantly co-ampliﬁed with MYC (KLF5:
p¼0.0005; GATA4:p ¼0.008; GATA6:p ¼0.01), while KLF5 and
GATA4 ampliﬁcations were mutually exclusive to one another
(p¼0.01).
Other notable ITR included a signiﬁcant co-ampliﬁcation
interaction between EGFR and MYC (p¼0.002) and between
ERBB2 and CCNE1 (p¼0.05) (ﬁgure 2B), a co-ampliﬁcation
pattern recently linked to trastuzumab resistance in breast
cancer.
37 Taken collectively, these results support the existence
of a complex functional network of ITR in gastric cancer. They
provide evidence that instead of each target behaving indepen-
dently from one another, the presence of one target in a gastric
cancer is likely to exert a profound inﬂuence on the repertoire of
other targets expressed in that same tumour.
Genomic alterations in RTK signaling genesdfrequent, mutually
exclusive and associated with patient survival in gastric cancer
Motivated by the clinical success of trastuzumab and the
availability of other RTK-targeting drugs in the gastric cancer
translational pipeline,
38 we decided to characterise the RTK
genomic alterations and their impacts on patient outcome. A
heat-map representation of the SNP array data conﬁrmed that
the four ampliﬁed RTK (FGFR2, ERBB2, EGFR and MET) were
mutually exclusive to one another (ﬁgure 3A). In addition, KRAS
genomic ampliﬁcations were also mutually exclusive to the
other RTK (ﬁgure 3A), suggesting these ﬁve components may
activate the same downstream pathway in gastric cancer (see
supplementary ﬁgure S5, available online only). The KRAS
ampliﬁcations are examined in more detail in the next section.
Taken collectively, RTK/RAS genomic ampliﬁcations occurred
in approximately 37% of the entire gastric cancer cohort (ﬁgure
3B). The most frequently ampliﬁed RTK/RAS component was
FGFR2 (9.3%), followed by KRAS (8.8%), EGFR (7.7%) and
ERBB2 (7.2%). Of 72 tumours exhibiting ampliﬁcation in at least
one RTK/RAS component, 73.6% (53/72) exhibited ampliﬁca-
tion of only one component, and 26.4% (19/72) tumours
exhibited high level ampliﬁcation of one component with low
level ampliﬁcation of another. Only two tumours exhibited high
level ampliﬁcation of two RTK/RAS components (black arrows
in ﬁgure 3A). Taken collectively, these results suggest that 37%
of the gastric cancer population is thus potentially targetable by
a RTK/RAS-directed therapy.
To assess the prognostic impact of RTK ampliﬁcations in
gastric cancer, we performed a survival analysis comparing the
clinical outcome of patients bearing tumours with RTK ampli-
ﬁcations compared with patients with tumours lacking RTK
ampliﬁcation. In a univariate analysis, patients with RTK
ampliﬁed tumours (FGFR2, ERBB2, EGFR, MET) experienced
poor survival outcome compared with patients with RTK
ampliﬁcation-negative cancers (p¼0.01, HR 1.636, 95% CI 1.101
Figure 2 Mutually exclusive and co-ampliﬁed genomic alterations. (A) Focal regions exhibiting mutually exclusive patterns of genome ampliﬁcation.
Chromosomal diagrams were created using Circos software.
36 Circular tracks from outside to in: genomic positions by chromosomes (black lines are
cytobands, red lines are centromeres); summarised CNA values in gastric tumours, summarised CNA values in normal gastric samples. Blue lines
indicate pairs of focal regions (genes) exhibiting signiﬁcant patterns of mutually exclusive genomic ampliﬁcation identiﬁed by dimension reduction
permutation (DRP) analysis (p<0.05; EGFR/KRAS,p ¼0.05). Genes involved in receptor tyrosine kinase (RTK)/RAS signalling are highlighted in red. (B)
Focal regions exhibiting patterns of genomic co-ampliﬁcation. Orange lines indicate pairs of focal regions (genes) exhibiting signiﬁcant patternso f
genomic co-ampliﬁcation identiﬁed by DRP analysis (p<0.05). Genes involved in RTK/RAS signalling are highlighted in red. Supplementary table S3
(available online only) provides a complete list of signiﬁcant mutually exclusive and co-alteration relationships for ampliﬁcations and deletions.
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Stomachto 2.432; ﬁgure 3C). Moreover, in multivariate Cox regression
models including RTK ampliﬁcation status, stage, grade and
treatment status (surgery alone or 5-FU adjuvant chemo-
radiation), RTK ampliﬁcation status was shown to be an inde-
pendent prognosis predictor (p¼0.01, HR 1.966, 95% CI 1.180 to
3.279; see supplementary table S4a, available online only). The
adverse prognosis of RTK-ampliﬁed gastric cancers was also
largely independent of chromosomal instability (p¼0.07), indi-
cating that it is not a mere consequence of increased aneuploidy
(see supplementary table S4a, available online only).
39
To evaluate individual RTK, we performed a follow-up
univariate Cox model analysis considering the four different
ampliﬁed RTK (FGFR2, ERBB2, EGFR and MET) as independent
factors. Patients with ERBB2-ampliﬁed tumours and MET-
ampliﬁed tumours were found to exhibit the worst prognosis
(ERBB2:p ¼0.0006, HR 2.824, 95% CI 1.558 to 5.119; MET:
p¼0.002, HR 2.744, 95% CI 1.190 to 6.327; see supplementary
table S4b, available online only). The adverse prognostic impact
of ERBB2 ampliﬁcation was also observed in a multivariate Cox
model with adjustment for tumour stage and grade (see
supplementary table S4c, available online only).
6 7 Therefore,
among the four different RTK, ERBB2 ampliﬁcations appear to
exert the strongest prognostic impact in gastric cancer.
KRAS-genomic ampliﬁcations highlight a previously
underappreciated gastric cancer subgroup
KRAS ampliﬁcations were frequently observed in our series,
occurring in 9% of patients. This ﬁnding is of interest, because
canonical activating mutations in KRAS at codons 12 and 13
are strikingly infrequent in gastric cancer, unlike other
Figure 3 Genomic alterations of receptor tyrosine kinase (RTK)/RAS signalling components in gastric cancer. (A) Mutually exclusive ampliﬁcation
patterns of RTK/RAS signalling components. In the heat-map, each row represents a different RTK/RAS signalling component. Each column represents
an individual tumour exhibiting RTK/RAS ampliﬁcation (72 tumours). The red colour gradient (top right) highlights the degree of copy number
ampliﬁcation. Black arrows highlight two tumours exhibiting high level ampliﬁcations in two RTK/RAS components. (B) Overall frequency of RTK/RAS
genomic alterations in gastric cancer. The pie chart displays the different gastric cancer subgroups exhibiting RTK/RAS ampliﬁcation. Gastric cancers
exhibiting at least one RTK/RAS ampliﬁcation event comprise a collective 37% of the gastric cancer cohort analysed. (C) KaplaneMeier survival
analysis comparing outcomes of patients with tumours exhibiting RTK ampliﬁcation (either FGFR2, ERBB2, EGFR,o rMET) ampliﬁcation to patients with
tumours lacking RTK ampliﬁcation. Patients with tumours exhibiting focal KRAS ampliﬁcations were included in analysis, and fall into the RTK low/no
CNA group. Overall survival was used as the outcome metric. (D) KaplaneMeier survival analysis comparing outcomes of patients with tumours
exhibiting KRAS ampliﬁcation (15 patients) to patients with non-RTK/KRAS-ampliﬁed tumours. Overall survival was used as the outcome metric. The
inset photo displays a patient tumour (ID 49375233) with KRAS ampliﬁcation conﬁrmed by ﬂuorescence in-situ hybridisation (FISH) analysis (blue,
DAPI nuclear stain; green, KRAS FISH probe; red, centromere 12 probe).
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40 41
Conﬁrming these earlier studies,
41 the KRAS mutation rate in our
own series was extremely lowdamong 139 gastric cancers
genotyped for KRAS codon 12 and 13 mutations, only one
tumour exhibited a KRAS mutation (G13D in 069LYK). We thus
hypothesised that KRAS genome ampliﬁcation, rather than
mutation, may represent a predominant mechanism for KRAS
activation in gastric cancer.
To obtain additional evidence that KRAS genomic ampliﬁca-
tions represent a distinct gastric cancer molecular subgroup, we
performed a KaplaneMeier survival analysis comparing
outcomes of patients with KRAS-ampliﬁed samples versus
patients with tumours lacking RTK or KRAS ampliﬁcation.
Patients with KRAS-ampliﬁed tumours exhibited signiﬁcantly
poorer prognosis (p¼0.01, HR 2.158, 95% CI 1.172 to 3.971;
ﬁgure 3D). Supporting the robustness of this survival associa-
tion, similarly signiﬁcant associations were observed when
patients with KRAS-ampliﬁed tumours were compared against
patients lacking KRAS ampliﬁcation but irrespective of RTK
ampliﬁcation, or when the copy number threshold deﬁning
KRAS ampliﬁcation was relaxed (p¼0.06, HR 1.744, 95% CI
0.973 to 3.127; p¼0.01, HR 1.665, 95% CI 1.114 to 2.488; see
supplementary ﬁgure S6, available online only).
To benchmark the prognostic effect of KRAS ampliﬁcation
against other RTK, we applied a univariate Cox regression model
consisting of all ﬁve genes. Similar to ERBB2 and MET ampliﬁ-
cations, gastric cancer patients with KRAS ampliﬁcations also
exhibited signiﬁcantly worse prognosis compared with patients
with tumours lacking either RTK or KRAS ampliﬁcations
(p¼0.02, HR 2.116, 95% CI 1.155 to 6.940; see supplementary
table S5a, available online only); however, this association may
be related to tumour stage (p¼0.2, HR 1.455, 95% CI 0.790 to
2.682; see supplementary table S5b, available online only).
Finally, to provide functional evidence that KRAS genomic
ampliﬁcation represents an important ‘driver’ event in KRAS-
ampliﬁed gastric cancers, we performed genetic knockdown
experiments. Small interfering RNA-mediated knockdown of
KRAS in KRAS ampliﬁed and KRAS-mutated gastric cancer cell
lines caused signiﬁcant reductions in proliferation but not in
KRAS wild-type lines, supporting an earlier report
41 (see
supplementary ﬁgure S7, available online only). These results
suggest that KRAS ampliﬁcation in gastric cancer probably
deﬁnes a speciﬁc subgroup of poor prognosis patients for which
KRAS signalling in tumours is critical.
FGFR2 ampliﬁcations in gastric cancer: relationships to gene
expression, clinical outcome and drug sensitivity
FGFR2 was being ampliﬁed in 9e10% of gastric cancers in our
series (table 1). Consistent with FGFR2 being the main driver of
ampliﬁcation in this locus, intersection of the ampliﬁcation
regions across 20 FGFR2-ampliﬁed tumours conﬁrmed that
FGFR2 was the sole gene in this region exhibiting common copy
number gain (ﬁgure 4A). Validating the SNP data, a quantitative
PCR analysis using primers directed towards FGFR2 conﬁrmed
that samples with high FGFR2 qPCR values were associated
with FGFR2 ampliﬁcation. (p¼0.0006, Fisher’s test; see supple-
mentary ﬁgure S8, available online only). FISH analysis using
BAC probes targeting FGFR2 also conﬁrmed FGFR2 gene
ampliﬁcation in patient tumours and cell lines, relative to
a centromere 10 probe (ﬁgure 4B).
FGFR2 has previously been proposed as a potential thera-
peutic target in gastric cancer,
38 but little is known regarding the
impact of FGFR2 ampliﬁcation on gene expression and other
clinicopathological parameters. To investigate relationships
between FGFR2 gene ampliﬁcation and FGFR2 gene expression,
we analysed gene expression proﬁle data for 156 of the 193
gastric cancers analysed by SNP arrays in this study, which we
have described in an earlier report.
42 FGFR2-ampliﬁed gastric
cancers indeed exhibited signiﬁcantly increased FGFR2 gene
expression levels (ﬁgure 4C and supplementary ﬁgure S9, avail-
able online only), when compared against a reference set of 100
normal gastric samples, or non-FGFR2-ampliﬁed tumours
(KruskaleWallis test p¼6.7e-9, Wilcoxon test p¼1.7e-7 (vs
normal) and p¼1.9e-5 (vs non-FGFR2-ampliﬁed gastric cancers).
In comparison, ATE1 and BRWD2, two genes located adjacent to
FGFR2 exhibited less signiﬁcant levels of copy number/gene
expression correlation (p¼0.004e0.3, relative to normals;
supplementary ﬁgure S10, available online only), further
supporting FGFR2 as the major driver gene in this region.
Examining clinicopathological variables, FGFR2-ampliﬁed
gastric cancers did not exhibit any signiﬁcant associations with
histology (Lauren’sp ¼0.8, grade p¼0.8 or tumour stage p¼0.9)
or patient survival (p¼0.8, see supplementary table S4b, avail-
able online only). However, in an expanded gene expression
dataset of 398 gastric tumours derived from four distinct cohorts
of which the previous 156 gastric cancers form a subset (see
supplementary information and supplementary table S6, avail-
able online only), high FGFR2 expression (compared with
normals, supplementary ﬁgure S11, available online only) was
associated with poor survival outcome in a univariate analysis
(p¼0.01, HR 1.492, 95% CI 1.094 to 2.035; ﬁgure 4D). In
a multivariate Cox regression model, samples with FGFR2 high
expression tended to exhibit borderline signiﬁcance after
adjusting for stage and grade (p¼0.08, HR 1.321, 95% CI 0.966
to 1.807; see supplementary table S7, available online only). This
result suggests that FGFR2 overexpression in gastric cancer may
be of prognostic relevance.
Dovitinib (TKI258) is an investigational multitargeting oral
tyrosine kinase inhibitor with potent inhibitory activity against
bFGF receptors 1, 2, 3, VEGF receptors 1, 2, 3, PDGFR and c-
KIT.
43 44 In preclinical models, dovitinib has exhibited anti-
tumour activity in FGFR1-ampliﬁed breast cancer,
45 and in
several phase I clinical trials has shown good therapeutic
proﬁles in human patients.
46 47 To test the potential efﬁcacy of
dovitinib in FGFR2-ampliﬁed gastric cancer, we treated FGFR2-
ampliﬁed and non-ampliﬁed gastric cancer lines (ﬁgure 5A) with
increasing dosages of dovitinib, to determine the GI50
concentration (the drug concentration required to cause 50%
growth inhibition). We observed potent growth inhibitory
activity of dovitinib speciﬁcally in FGFR2-ampliﬁed gastric
cancer cell lines with GI50 dosages in the submicromolar range
(KATO-III 0.12 mM; SNU-16 0.17 mM, ﬁgure 5B). Decreased
phosphorylation of FGFR2, ERK and AKT was also observed
after 1 h of dovitinib treatment (ﬁgure 5C). Besides inhibiting
cell proliferation, dovitinib treatment also induced a signiﬁcant
decrease in soft-agar colony formation in FGFR2-ampliﬁed lines
(KATO III p¼0.002; SNU16 p¼0.05; ﬁgure 5D and supple-
mentary ﬁgure S12, available online only). In a cell death
assay, dovitinib treatment induced apoptosis, measured by
caspase 3/7 activation, in SNU-16 cells after 24 h of treatment,
but not in KATO III cells (ﬁgure 5E). These results suggest that
dovitinib treatment can inhibit several pro-oncogenic traits in
FGFR2-ampliﬁed lines, but additional factors may be required
for FGFR2-ampliﬁed cells to undergo apoptosis upon dovitinib
treatment.
To evaluate the efﬁcacy of dovitinib in an in-vivo model, we
performed drug treatment experiments using an FGFR2-ampli-
ﬁed primary human gastric cancer xenograft model, comparing
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tumour sizes of vehicle-treated mice reached 1163 mm
3 at day
25 post-treatment, while treatment with 5-FU at 20 mg/kg (qd
3 5/week 3 2 weeks, intraperitoneally) produced a reduced
mean tumour size of 518 mm
3 (total growth inhibition 63%,
p¼0.08) after the same period. Importantly, treatment with
dovitinib at 30 mg/kg and 50 mg/kg (qd 3 25 days, by mouth)
signiﬁcantly inhibited tumour growth compared with vehicle-
treated tumours (p¼0.006 and 0.002, respectively), with ﬁnal
tumour sizes of 194 and 53 mm
3, respectively, at day 25 post-
treatment (ﬁgure 5F). Dovitinib may thus represent a promising
subtype-speciﬁc therapy for FGFR2-ampliﬁed gastric cancers.
DISCUSSION
Here we report a high-resolution genomic analysis of a large
cohort of gastric cancer primary tumours and cell lines delin-
eating the most prevalent molecular targets in this disease.
While earlier reports analysing gastric cancer copy number
alterations have largely analysed small patient populations or
used low-resolution technologies (eg, chromosomal CGH),
22e26
these earlier studies were invaluable in benchmarking the
reproducibility of our own data. For example, in a recent copy
number analysis of 49 gastric cancers using Agilent 44k arrays,
27
concordant regions commonly identiﬁed in that study and ours
include the frequent broad ampliﬁcations of chromosome 8 and
Figure 4 FGFR2 gene ampliﬁcation and messenger RNA expression in gastric cancer. (A) Heat-map showing the FGFR2 gene ampliﬁcation region in
individual gastric cancer samples (20 tumours). Each row indicates one gastric cancer sample with the ampliﬁed region in red. Intensity of the red bar
indicates the level of copy number ampliﬁcation. Genes located in this region are shown at the bottom. The intersection of these ampliﬁed regions
covers only the FGFR2 gene (red box, gene outlined at bottom). (B) FGFR2 genomic ampliﬁcation conﬁrmed by ﬂuorescence in-situ hybridisation
(FISH). The photo displays a patient tumour (ID 21080055) with FGFR2 ampliﬁcation and two FGFR2-ampliﬁed cell lines KATO-III and SNU16 conﬁrmed
by FISH analysis. Green signals indicate the FGFR2 FISH probe, red signals probes to centremore 10. (C) FGFR2 gene expression in clinical specimens.
FGFR2 gene expression was compared across three categories, each represented by a box-plot: non-malignant gastric tissues (normal) (n¼100);
tumours exhibiting no/low FGFR2 CNA (n¼139); and tumours exhibiting high FGFR2 CNA (n¼17). mRNA comparisons were based on 156 gastric
cancers in which gene expression data were available, representing a subset of the 193 gastric cancers analysed by single nucleotide polymorphism
arrays. FGFR2 gene expression was inferred from Affymetrix microarrays (FGFR2 probe 211401_s_at). FGFR2 mRNA levels are signiﬁcantly higher in
samples with FGFR2 high CNA compared with the other two categories (p¼6.7e-9, KruskaleWallis test). Tumours exhibiting FGFR2 ampliﬁcation
exhibit signiﬁcantly increased FGFR2 gene expression compared with tumours exhibiting no/low FGFR2 CNA or non-malignant samples (p¼1.9e-5 and
1.7e-7, Wilcoxon test). (D) KaplaneMeier survival analysis comparing patients with tumours exhibiting high FGFR2 gene expression, deﬁned as
twofold higher than the average FGFR2 gene expression level in normal samples (72 tumours), with patients with tumours exhibiting low FGFR2 gene
expression (total 398 patients, the 156 patients analysed in ﬁgure 4C are a subset of these 398 patients). Overall survival was used as the outcome
metric.
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EGFR, GATA4, MYC, KRAS and CCNE1. However, reﬂecting the
increased size (193 vs 49) and resolution (44 K vs 1.8 million SNP
probes) of our study, we also detected ampliﬁcations of chro-
mosome 18 and deletions of chromosome 6q, which were not
detected in earlier work.
22e27
Using GISTIC, we identiﬁed 22 recurrently altered regions in
gastric cancer that are likely to represent the most prevalent
Figure 5 Sensitivity of FGFR2-ampliﬁed gastric cancer cell lines to dovitinib. (A) (Top) FGFR2 reverse transcription PCR analysis of gastric cancer cell
lines. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. (Bottom) FGFR2 protein expression in lines. b-actin was
used as a loading control. Cell lines KATOIII and SNU16 are observed to express elevated levels of FGFR2 mRNA and protein. (B) Cell proliferation
effects of dovitinib treatment. Dovitinib GI50 values for FGFR2-ampliﬁed and non-ampliﬁed cell lines. GI50, drug concentration required to cause 50%
growth inhibition. GI50 values were calculated after 48 h dovitinib treatment. *p<0.05 compared with non-ampliﬁed lines. Results are a mean of three
independent experiments. (C) Molecular effects of dovitinib treatment. Cells treated with dovitinib at 50 nM, 100 nM and 500 nM concentrations for
1 h. Lysates were immunoprecipitated with FGFR2 anitbody MAB6841, and probed with 4G10 (phosphotyrosine detection) or MAB6841 for total
FGFR2. Other antibodies included total and phospho-ERK, and total and phospho-AKT. Experiments were repeated a minimum of three independent
times. (D) Dovitinib inhibits soft agar colony formation. FGFR2-ampliﬁed cells were treated with dovitinib at the GI50 concentration for each cell line
(KATO-III 0.12 mM; SNU-16 0.17 mM) for 48 h, and soft-agar colony formation monitored over the subsequent 3e4 weeks. Data for KATO-III cells are
provided, including representative colony plates. Similar results were observed for SNU16 (see supplementary ﬁgure S9, available online only). (E)
Dovitinib induces caspase-3 activation. FGFR2-ampliﬁed cells were treated with increasing dovitinib concentrations, and apoptosis levels measured
after 24 h using Caspase-Glo 3/7 assays. The y-axis represents the percentage of activation normalised against untreated controls. The results are
a mean of triplicates 6SD. Experiments were repeated three independent times. (F) Dovitinib inhibits tumour growth in a human primary gastric cancer
xenograft model bearing FGFR2 gene ampliﬁcation. The mean tumour size of the vehicle-treated mice reached 1163 mm
3 at day 25 post-treatment.
Treatment with the positive control drug 5-FU at 20 mg/kg (qd 3 5/week 32 weeks, intraperitoneally) produced a mean tumour size of 518 mm
3 (total
growth inhibition 63%, p¼0.08) at the same time. Treatment with dovitinib at 30 mg/kg and 50 mg/kg (qd 325 days, by mouth) signiﬁcantly inhibited
tumour growth compared with vehicle-treated animals, with a mean tumour size of 194 and 53 mm
3, respectively (p¼0.006 and 0.002, respectively, at
day 25 post-treatment).
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conﬁrmed the SNP array results using a variety of orthogonal
methodologies, including immunohistochemistry, FISH and
qPCR. A survey of genes in the 22 altered regions revealed that
they could be broadly partitioned into three major functional
categories: RTK/RAS signalling (FGFR2, KRAS, ERBB2, EGFR,
MET); transcriptional regulation (MYC, GATA4, GATA6, KLF5)
and cell cycle control (CCND1, CCNE1, CDK6, CDKN2A/B, RB).
As expected, many of these genes were already known to be
associated with genomic alterations in gastric cancer.
6 11 28 29
Critically, however, our analysis also identiﬁed several novel
genes not previously known to be ampliﬁed or deleted in gastric
cancer. For example, we observed for the ﬁrst time frequent
deletions of PARK2, a E3 ubiquitin ligase, in gastric cancer.
48
Mutations in PARK2 have been associated with early-onset
Parkinson’s disease,
49 and more recently PARK2 mutations and
deletions have been observed in other cancers.
50 Another novel
altered gastric cancer gene was CSMD1, a gene of uncertain
function but that has been proposed as a tumour suppressor in
breast cancer.
51 Using immunohistochemistry, we conﬁrmed
that up to 40% of gastric cancers can exhibit CSMD1 protein
loss or reduced expression. Addressing the functions of these
novel altered genes, given their frequency of alteration in gastric
cancer, will probably be an important goal of future research
work. In addition, our study also highlights interesting thera-
peutic opportunitiesdfor example, the cyclin-dependent kinase
CDK6 was frequently ampliﬁed in our series, and small mole-
cule-targeted inhibitors of CDK have been developed.
52
A notable ﬁnding in this study was that GATA4, GATA6 and
KLF5 are frequently ampliﬁed in gastric cancer. Notably, GATA4
ampliﬁcations in gastric cancer have also been observed by other
groups.
53 Intriguingly, when compared against genes identiﬁed
as ampliﬁed in other comparable copy number studies from
glioblastoma, lung cancer and multiple cancer types,
19e21 it
appears that ampliﬁcation of these three genes appears to be
restricted to either gastric cancer or to other cancers related to
gastrointestinal tract origin. It is possible that these genes may
represent ‘lineage-speciﬁc’ oncogenes, a recently described class
of cancer genes that enhance oncogenesis by reactivating
lineage-speciﬁc survival mechanisms normally operative only in
early embryonic development.
54 Examples of lineage survival
oncogenes include MITF in melanoma, TITF1/NKX2.1 in lung
cancer
55 56 and SOX2 in oesophageal and lung cancers.
57 Indeed,
GATA6 has recently been proposed to function as an ampliﬁed
lineage-survival oncogene in pancreatic cancer,
35 58 and KLF5 has
been shown to be expressed during early development in the
cardiovascular system and gastrointestinal tract epithelium in
the proliferating zone of intestinal crypts.
59 60 These transcrip-
tion factors may reﬂect the existence of an underlying tran-
scriptional regulatory programme important for the
maintenance of the gastric cancer phenotype. Interestingly,
a recent genomic study from our group reported the discovery of
two gastric cancer subtypes (G-INT and G-DIF) with distinct
gene expression, clinical outcome and chemotherapy response
features.
61 We have since discovered that G-DIF gastric cancers
appear to be signiﬁcantly enriched in GATA6 gene ampliﬁcations
(Fisher’s exact test, p¼0.04), suggesting that GATA6 may be
associated with a speciﬁc molecular subtype of gastric cancer.
From a therapeutic perspective, transcription factors are
commonly regarded as ‘undruggable’. It is possible, however,
that some of these transcription factors may regulate the
expression of key genes that are pharmacologically target-
able. For example, BCL2 has been described as a target of the
MITF transcription factor frequently ampliﬁed in melanoma,
62
and BCL2 inhibitor drugs are available. Such a strategy may
represent one method to target ampliﬁed transcription factors
indirectly.
Of major clinical signiﬁcance was the observation that genes
related to RTK/RAS signalling are frequently altered and
mutually exclusive to one another in gastric cancer. First,
because numerous targeted inhibitors directed against various
components of the RTK/RAS pathway are already in clinical
testing,
4 9 these results raise the possibility that a substantial
proportion (37% of gastric cancers) may be potentially target-
able by a RTK/RAS-directed therapy. In essence, this ﬁnding
dramatically increases the population of gastric cancer patients
for which targeted treatments could be considered. Second, the
mutually exclusive nature of these RTK/RAS alterations
strongly suggests that the majority of gastric cancers are likely
to have only a single RTK/RAS driver oncogene, thereby greatly
simplifying the challenge of deﬁning which RTK/RAS targeted
inhibitor compound to allocate to which patient population. In
terms of clinical trials, the mutually exclusive nature of the
RTK/RAS alterations also renders it technically feasible to
implement a multibiomarker-based trial,
63 in which multiple
targeted compounds are tested in different biomarker-deﬁned
populations within a single trial design, as has been recently
described for non-small-cell lung cancer (BATTLE trial).
64 Third,
these results suggest that a much larger proportions of gastric
cancers may be reliant on RTK/RAS signalling than previously
appreciated, particularly if one notes that in this study alter-
native mechanisms of RTK/RAS activation were not considered,
and for certain gastric cancers the presence of non-malignant
cells may have reduced the sensitivity of RTK/RAS alteration
detection. For example, in a recent kinome sequencing study,
kinases related to MAPK signalling, a pathway downstream of
KRAS, were identiﬁed as being the most signiﬁcantly altered in
gastric cancer.
65 Another alternative mechanism of RTK/RAS
activation may also involve gene fusions, in which we recently
described RAF-related gene rearrangements in gastric cancer.
66
Taken collectively, we believe that our ﬁnding that 37% of
gastric cancers exhibit a RTK/RAS alteration should best be
regarded as a lower limit, and are consistent with the notion
that RTK/RAS signalling is a dominant oncogenic pathway in
gastric cancer.
In our series, FGFR2 was ampliﬁed at frequencies comparable
to ERBB2, providing one of the ﬁrst assessments of FGFR2 gene
ampliﬁcation in primary gastric cancers. Interestingly, the
smallest common peak of FGFR2 ampliﬁcation in the gastric
cancers appears to centre around a 1.5 kb region in FGFR2 intron
2, which overlaps a SNP locus associated with breast cancer
susceptibility.
67 It is intriguing to consider whether the process
of genomic ampliﬁcation might also bias the expression of the
FGFR2 gene towards transcript isoforms (IIIc) that are pro-
oncogenic.
68 We also found that in preclinical assays, dovitnib,
a VEGFR/FGFR2 inhibitor, can potently inhibit the growth of
FGFR2-ampliﬁed gastric cancer cell lines and xenografts. In
breast cancer, dovitinib has been found to exert effects primarily
in FGFR1-ampliﬁed breast cancers, suggesting the importance of
FGFR-related genome ampliﬁcation in predicting dovitinib
response.
69 FGFR2 is thus likely to represent an attractive
therapeutic target in gastric cancer. However, one question not
addressed by our data is whether gastric cancers that lack FGFR2
ampliﬁcation, but nevertheless express FGFR2, will also be
dovitnib responsive, as we also observed that a signiﬁcant
number of FGFR2 copy-neutral tumours also exhibited elevated
FGFR2 expression levels relative to matched normal tissues,
indicating that other mechanisms besides gene ampliﬁcation can
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study showed that FGFR2 inhibition can potentially reverse
chemoresistance in OCUM-2M gastric cancer cells, which are
also FGFR2 copy-number ampliﬁed.
70 We are currently
addressing these questions by conducting a biopsy-mandated
phase I/II trial at our centre, evaluating the efﬁcacy of dovitinib
in FGFR2-ampliﬁed and FGFR2-expressing gastric cancer
samples.
Finally, our results highlight KRAS ampliﬁcation (rather than
KRAS mutation) as a prevalent event in gastric cancer. While
KRAS ampliﬁcations have been reported in other cancers (eg,
lung),
71 these observations have been largely anecdotal, with
emphasis directed towards more conventional codon 12 and 13
activating mutations. Consistent with KRAS activating as an
important driver gene in ampliﬁed samples, patients in our series
with KRAS-ampliﬁed gastric cancers exhibited poor prognosis,
and in vitro, KRAS-ampliﬁed gastric cancer lines were sensitive
to KRAS silencing, similar to KRAS mutated lines. The high
frequency of KRAS ampliﬁcations in gastric cancer is probably
a major reason why KRAS activating mutations are strikingly
infrequent in gastric cancer.
41 However, the exact mechanisms
underlying this striking tissue-speciﬁc preference for KRAS
ampliﬁcation remain to be elucidated. Nevertheless, given recent
data demonstrating that KRAS-mutated colon cancers are
resistant to anti-EGFR therapies,
72 and that KRAS-ampliﬁed
tumours may be resistant to MEK1/2 inhibitors,
73 our ﬁndings
strongly suggest that testing KRAS ampliﬁcation status in
tumours should be fully considered in any trials evaluating RTK-
targeting compounds in gastric cancer.
In conclusion, our results provide for the ﬁrst time a detailed
molecular map of genomic alterations in gastric cancer, which
has revealed several promising targets for subtype-speciﬁc ther-
apies. Classifying gastric cancer patients by these signature
genomic alterations may facilitate patient allocations to the
most appropriate clinical trials, thereby maximising patient
participation in combatting this lethal disease.
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